Bladder cancer stage I with cancer in situ – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bladder cancer stage I with cancer in situ – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of TARA-002 for Adults with High-Grade Non-Muscle Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tara-002-for-adults-with-high-grade-non-muscle-invasive-bladder-cancer/ Wed, 29 Apr 2026 14:26:59 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tara-002-for-adults-with-high-grade-non-muscle-invasive-bladder-cancer/ This clinical trial is focused on studying a type of bladder cancer known as high-grade non-muscle invasive bladder cancer. The treatment being tested is called TARA-002, which is a form of inactivated bacteria known as Streptococcus pyogenes. This treatment is administered directly into the bladder through a process called intravesical instillation, which involves placing the medication directly into the bladder.

The purpose of the study is to evaluate the safety and effectiveness of TARA-002 in treating this type of bladder cancer. Participants in the study will receive the treatment and will be monitored for any changes in their condition. The study will also look at how the treatment affects the cancer and any side effects that may occur. The study is divided into two groups, with each group receiving the treatment and undergoing regular check-ups to assess the treatment’s impact on their cancer.

Throughout the study, participants will have regular medical evaluations, including procedures like cystoscopy (a test that allows doctors to look inside the bladder), bladder biopsies (taking a small sample of bladder tissue for testing), and urine tests. These evaluations will help determine how well the treatment is working and ensure the safety of the participants. The study aims to provide valuable information on the potential benefits of TARA-002 for people with high-grade non-muscle invasive bladder cancer.

]]>